{
  "id": "fda_guidance_chunk_0281",
  "title": "Introduction - Part 281",
  "text": "if needed by the sponsor. 5.5.12 The sponsor should inform the investigator(s)/institution(s) in writing of the need for record retention and should notify the investigator(s)/institution(s) in writing when the trial-related records are no longer needed. 5.6 Investigator Selection Contains Nonbinding Recommendations 5.6.1 The sponsor is responsible for selecting the investigator(s)/institution(s). Each investigator should be qualified by training and experience and should have adequate resources (see sections 4.1, 4.2) to properly conduct the trial for which the investigator is selected. If organization of a coordinating committee and/or selection of coordinating investigator(s) are to be utilized in multicenter trials, their organization and/or selection are the sponsor's responsibility. 5.6.2 Before entering an agreement with an investigator/institution to conduct a trial, the sponsor should provide the investigator(s)/institution(s) with the protocol and an up-to-date Investigator's Brochure, and should provide sufficient time for the investigator/institution to review the protocol and the information provided. 5.6.3 The sponsor should obtain the investigator's/institution's agreement: (a) To conduct the trial in compliance with GCP, with the applicable regulatory requirement(s) (see section 4.1.3), and with the protocol agreed to by the sponsor and given approval/favorable opinion by the IRB/IEC (see section 4.5.1); (b) To comply with procedures for data recording/reporting; (c) To permit monitoring, auditing, and inspection (see section 4.1.4); and (d) To retain the trial-related essential documents until the sponsor informs the investigator/institution these documents are no longer needed (see sections 4.9.4 and 5.5.12). The sponsor and the investigator/institution should sign the protocol, or an alternative document, to confirm this agreement. 5.7 Allocation of Responsibilities Prior to initiating a trial, the sponsor should define, establish, and allocate all trial-related duties and functions. 5.8 Compensation to Subjects and Investigators 5.8.1 If required by the applicable regulatory requirement(s), the sponsor should provide insurance or should indemnify (legal and financial coverage) the investigator/the institution against claims arising from the trial, except for claims that arise from malpractice and/or negligence. 5.8.2 The sponsor's policies and procedures should address the costs of treatment of trial subjects in the event of trial-related injuries in accordance with the applicable regulatory requirement(s). 5.8.3 When trial subjects receive compensation, the method and manner of compensation should comply with applicable regulatory requirement(s). 5.9 Financing The financial aspects of the trial should be documented in an agreement between the sponsor Contains Nonbinding Recommendations and the",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 376320,
  "end_pos": 377856,
  "tokens": 512,
  "tags": [
    "regulatory",
    "clinical_trial",
    "consent",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "recommendation",
  "created_at": "2025-10-23T02:25:44.697Z"
}